A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours.

Kim, Hyung-Don; Yoo, Changhoon; Ryu, Min-Hee; Kang, Yoon-Koo

Kim, Hyung-Don; Yoo, Changhoon; Ryu, Min-Hee; Kang, Yoon-Koo.

Afiliação

Kim HD; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Yoo C; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Ryu MH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Kang YK; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. ykkang@amc.seoul.kr.

Br J Cancer ; 129(2): 275-282, 2023 08.

Article em En | MEDLINE | ID: mdl-37179439

Assuntos

Antineoplásicos; Tumores do Estroma Gastrointestinal; Humanos; Antineoplásicos/efeitos adversos; Tumores do Estroma Gastrointestinal/patologia; Mesilato de Imatinib; Inibidores de Proteínas Quinases; Sunitinibe/uso terapêutico; Resultado do Tratamento

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tumores do Estroma Gastrointestinal / Antineoplásicos Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google